Acorda Therapeutics, Inc. (NASDAQ:ACOR).
The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw a one year low price at $21.70 as trading wrapped up on Wednesday. The stock traded down at $21.98. Volume was 1,158,782 shares and the stock hit a high of $22.36.
Shares of the company closed at $21.98 which is marginally under $24.82, the 50 day moving average and a bit lower than the 200 day moving average of $26.14. The 50 day moving average was down by -11.46% whereas the 200 day moving average was down $-4.16 or -15.93%.
As of the last earnings report the EPS was $-0.14 and is expected to be $0.47 for the current year with 46,090,000 shares outstanding. Next quarter’s EPS is estimated at $0.14 and the next full year EPS is projected to be $0.68.
Investors are feeling more bullish on the company recently at least if you consider the motion in short interest. The stock experienced a fall in short interest of -0.01% between August 31, 2016 and September 15, 2016. Short shares fell 41,945 over that period. With short interest at 5,509,110 and short average daily volume at 419,012, days to cover is 13.1 and the short interest percentage is 0.12% as of September 15.
Analysts have released opinions. On March 30, 2016 Goldman Sachs released its first research report on the stock by announcing an initial rating of “Neutral” and price target of $23.00. January 6 investment analysts at Aegis Capital kept the company rating at “Buy” and moved up the price target from $40.00 to $52.00.
Guggenheim Securities began coverage of the stock setting a rating of “Neutral”. On April 22 analysts at Piper Jaffray issued its first research report on the stock giving it an initial rating of “Neutral”.
On February 13 Citigroup held the stock rating at “Neutral” and lowered the price target to $42.00 from $46.00. Equity analyst MLV & Co. starting coverage on the stock with a rating of “Buy” and a price target of $58.00.